[go: up one dir, main page]

MX359639B - Metodos y composiciones para uso en tratamientos celulares. - Google Patents

Metodos y composiciones para uso en tratamientos celulares.

Info

Publication number
MX359639B
MX359639B MX2012000396A MX2012000396A MX359639B MX 359639 B MX359639 B MX 359639B MX 2012000396 A MX2012000396 A MX 2012000396A MX 2012000396 A MX2012000396 A MX 2012000396A MX 359639 B MX359639 B MX 359639B
Authority
MX
Mexico
Prior art keywords
methods
compositions
cellular therapies
therapies
cellular
Prior art date
Application number
MX2012000396A
Other languages
English (en)
Other versions
MX2012000396A (es
Inventor
Lombardo Eleuterio
Buscher Dirk
Original Assignee
Cellerix Sa Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellerix Sa Star filed Critical Cellerix Sa Star
Publication of MX2012000396A publication Critical patent/MX2012000396A/es
Publication of MX359639B publication Critical patent/MX359639B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a un citoblasto de mesenquina para usar en el tratamiento, modulación, disminución y/o profilaxis de un trastorno inflamatorio y/o inmunitario en donde el citoblasto de mesénquima es administrble al sistema linfático por inyección intralinfática. Y una composición farmaceúticamente comprende al citoblasto.
MX2012000396A 2009-07-09 2010-07-09 Metodos y composiciones para uso en tratamientos celulares. MX359639B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22427509P 2009-07-09 2009-07-09
PCT/IB2010/001968 WO2011004264A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Publications (2)

Publication Number Publication Date
MX2012000396A MX2012000396A (es) 2012-07-17
MX359639B true MX359639B (es) 2018-10-04

Family

ID=42782196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000396A MX359639B (es) 2009-07-09 2010-07-09 Metodos y composiciones para uso en tratamientos celulares.

Country Status (19)

Country Link
US (1) US8679834B2 (es)
EP (2) EP3150703A1 (es)
JP (1) JP5892931B2 (es)
KR (1) KR101788885B1 (es)
CN (2) CN107007626A (es)
AU (1) AU2010269962B2 (es)
BR (1) BR112012000534A2 (es)
CA (1) CA2767300C (es)
DK (1) DK2451943T3 (es)
ES (1) ES2479542T3 (es)
HU (1) HUE031921T2 (es)
IL (1) IL217377A (es)
MX (1) MX359639B (es)
NZ (1) NZ597975A (es)
PL (1) PL2451943T3 (es)
PT (1) PT2451943T (es)
RU (1) RU2610427C2 (es)
SG (2) SG177582A1 (es)
WO (1) WO2011004264A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
KR101900664B1 (ko) * 2011-01-12 2018-09-21 타이제닉스, 에스.에이.유. 자가면역 및 염증성 질환에서 림프내 투여를 위한 지방-유래 중간엽 줄기 세포
CN104136034B (zh) 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016107563A1 (zh) * 2014-12-29 2016-07-07 西比曼生物科技（上海）有限公司 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物
CN107864627A (zh) 2015-03-23 2018-03-30 普拉里斯坦有限公司 包含粘附基质细胞的方法和组合物
EP3416662B1 (en) 2016-02-18 2020-07-29 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN107349419A (zh) * 2017-07-17 2017-11-17 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN107281469A (zh) * 2017-07-17 2017-10-24 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
EP3851112A4 (en) * 2018-09-14 2022-07-27 Luca Science Inc. TRANSPLANTATION OF MITOCHONDRIA IN A LYMPHOID ORGAN AND ASSOCIATED COMPOSITION
AU2020240049A1 (en) * 2019-03-19 2021-11-04 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006951A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
BRPI0317064B8 (pt) * 2002-12-06 2021-05-25 Northwest Biotherapeutics Inc composições compreendendo células dendríticas parcialmente amadurecidas in vitro
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
US20090324609A1 (en) * 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US20110262402A1 (en) * 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells

Also Published As

Publication number Publication date
PT2451943T (pt) 2017-01-20
SG10201403758SA (en) 2014-10-30
CA2767300C (en) 2020-01-07
RU2610427C2 (ru) 2017-02-10
CN107007626A (zh) 2017-08-04
PL2451943T3 (pl) 2017-04-28
EP2451943B1 (en) 2016-11-23
RU2012104529A (ru) 2013-08-20
AU2010269962B2 (en) 2016-04-14
WO2011004264A1 (en) 2011-01-13
JP2012532859A (ja) 2012-12-20
JP5892931B2 (ja) 2016-03-23
MX2012000396A (es) 2012-07-17
ES2479542T1 (es) 2014-08-20
AU2010269962A1 (en) 2012-03-01
US20120308585A1 (en) 2012-12-06
HUE031921T2 (en) 2017-08-28
NZ597975A (en) 2014-06-27
CN102549147A (zh) 2012-07-04
SG177582A1 (en) 2012-03-29
US8679834B2 (en) 2014-03-25
KR101788885B1 (ko) 2017-10-20
CA2767300A1 (en) 2011-01-13
IL217377A0 (en) 2012-02-29
KR20120051006A (ko) 2012-05-21
EP3150703A1 (en) 2017-04-05
IL217377A (en) 2017-10-31
ES2479542T3 (es) 2017-05-26
DK2451943T3 (en) 2017-02-06
EP2451943A1 (en) 2012-05-16
BR112012000534A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2013012184A (es) Composiciones formadoras de gel in situ.
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MY161601A (en) Films and compositions comprising the same
WO2012095743A3 (en) Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
PH12013500500A1 (en) Fused heteroaryls and their uses
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
IN2012DN03404A (es)
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
WO2012016026A3 (en) Electrolarynx devices and uses thereof
MX2013008559A (es) Derivados de leptina.

Legal Events

Date Code Title Description
FG Grant or registration